❤️ Category
Peptides for Sexual Health & Libido
Melanocortin-system peptides studied for libido and arousal, including one FDA-approved drug.
Melanocortin-system peptides studied for libido and arousal, including one FDA-approved drug.
Sexual-health peptides act mainly on two systems. The melanocortin system influences sexual desire in the brain — this is how PT-141 (bremelanotide), an FDA-approved drug for low sexual desire in women, works, distinct from blood-flow drugs like Viagra. The GnRH (gonadotropin) system controls the reproductive hormone cascade.
GnRH peptides illustrate a neat pharmacological paradox: given in pulses, gonadorelin stimulates sex hormones, but continuous leuprolide (a GnRH agonist) ultimately suppresses them, while cetrorelix (a GnRH antagonist) blocks them immediately — each property is used in different treatments, from IVF to prostate cancer. Kisspeptin, the master switch above GnRH, is an active research frontier for fertility and desire.
A melanocortin receptor agonist and, as bremelanotide (Vyleesi), an FDA-approved treatment for hypoactive sexual desire disorder in premenopausal women.
Read the guide →A synthetic melanocortin agonist researched for skin tanning and, secondarily, libido — but with notable safety concerns and no approval.
Read the guide →A neuropeptide that is a master regulator of reproductive hormones, studied for fertility disorders and, more recently, sexual and emotional brain processing.
Read the guide →Synthetic gonadotropin-releasing hormone (GnRH) that stimulates the pituitary to release LH and FSH — historically an approved agent for diagnosis and fertility, and used by some clinicians during testosterone therapy.
Read the guide →A natural hormone and neuropeptide central to bonding, birth, and lactation — FDA-approved for obstetric use (as Pitocin) and widely researched (often intranasally) for social and emotional behavior.
Read the guide →A GnRH agonist and widely used FDA-approved drug (Lupron) that, with continuous dosing, suppresses sex hormones — used in prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.
Read the guide →A GnRH receptor antagonist and FDA-approved drug (Cetrotide) used during IVF to prevent a premature LH surge and early ovulation.
Read the guide →A GnRH agonist delivered as a long-acting subcutaneous implant (Zoladex), FDA-approved for prostate cancer, certain breast cancers, and endometriosis.
Read the guide →A GnRH agonist given as a depot injection (Trelstar, Decapeptyl), used for advanced prostate cancer, central precocious puberty, and endometriosis.
Read the guide →A GnRH agonist delivered as a nasal spray (Synarel), FDA-approved for endometriosis and central precocious puberty.
Read the guide →A GnRH antagonist (Firmagon), FDA-approved for advanced prostate cancer, that lowers testosterone rapidly without the initial flare seen with GnRH agonists.
Read the guide →A GnRH agonist delivered as a once-yearly subcutaneous implant, FDA-approved for central precocious puberty (Supprelin LA) and prostate cancer (Vantas).
Read the guide →A long-acting analog of oxytocin used to prevent postpartum hemorrhage after delivery; approved in many countries (and available as a heat-stable formulation), though not FDA-approved in the US.
Read the guide →The body's natural melanocortin hormone — central to skin pigmentation, inflammation, and appetite — and the biology that synthetic analogs like melanotan and bremelanotide (PT-141) are designed to imitate.
Read the guide →This category contains two groups of compounds that work in unrelated ways and are frequently confused with each other.
Melanocortin peptides act on the brain. PT-141 (bremelanotide) and Melanotan II activate melanocortin receptors involved in sexual desire. This is a fundamentally different target from the established erectile-dysfunction medications, which work on blood flow in the periphery. PT-141 is FDA-approved, but specifically for hypoactive sexual desire disorder in premenopausal women — not for erectile dysfunction, and not for men. Melanotan II is unapproved, sold mainly for tanning, and carries genuine concerns including changes to moles.
GnRH-system peptides act on the hormonal axis. Gonadorelin, leuprolide, goserelin, triptorelin, cetrorelix and degarelix act on the signalling that controls sex-hormone production. Most are approved medicines used in prostate cancer, endometriosis, fibroids, fertility treatment and precocious puberty — clinical uses that have little to do with the "sexual health" framing this category name implies.
A structural quirk worth knowing: GnRH agonists initially stimulate the axis and then shut it down through continuous stimulation, while antagonists block it immediately. Opposite starting behaviour, similar endpoint.
Because the two groups above are so different, the practical picture divides cleanly.
The approved medicines here are real and well-evidenced — but they are oncology, fertility and endocrine drugs prescribed for specific diagnoses, not enhancement compounds. Leuprolide is a prostate cancer therapy. Cetrorelix prevents premature ovulation in IVF cycles. These belong to clinical medicine.
For men specifically, this category is often misrepresented. No peptide here is a testosterone replacement — testosterone is a steroid hormone, not a peptide, and the two are different classes of molecule. Compounds like gonadorelin and kisspeptin act upstream on the axis that controls testosterone production, which depends on that axis being intact and is a genuinely different intervention from replacement. See peptides for men.
Oxytocin occupies its own space: an approved medicine used in obstetrics, and simultaneously the subject of a large body of research on social behaviour and bonding, where results have been considerably less consistent than popular coverage suggests.
Anyone with a sexual-health concern is dealing with something that frequently has an identifiable and treatable cause — cardiovascular, hormonal, psychological or medication-related. That is a diagnosis worth having rather than a problem to self-treat with a research chemical.
No. Viagra (sildenafil) is a PDE5 inhibitor that improves erectile blood flow, whereas PT-141 (bremelanotide) acts centrally on melanocortin receptors involved in sexual desire. PT-141 is FDA-approved (as Vyleesi) for low sexual desire in premenopausal women.
Delivery and mechanism differ. Pulsatile gonadorelin (a GnRH) stimulates hormone release; continuous leuprolide (a GnRH agonist) overstimulates and then desensitizes the receptors, suppressing hormones after an initial flare; cetrorelix (a GnRH antagonist) blocks the receptor directly with no flare.
PT-141 (bremelanotide/Vyleesi), leuprolide (Lupron), and cetrorelix (Cetrotide) are FDA-approved for their respective indications. Kisspeptin is investigational, and 'PT-141' sold as a research chemical is not the approved product.